Also known as MK-6482 and WELIREG.
Phase 3 intismeran combo improved recurrence‑free and distant metastasis‑free survival in resected stage IIB–IV melanoma; sac‑TMT and KEYNOTE‑C93 report pivotal endometrial cancer findings; >90 additional abstracts.
FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.
